Clinical trials: Virologic Failure
Viral Resistance, Treatment Failure
Virologic Treatment Failure and Drug Resistance in HIV-infected Kenyan Children (RESPECT)
The primary objective of this study is to use a well-characterized pediatric AMPATH cohort, with detailed medication-taking, drug level, and clinical data, to longitudinally evaluate treatment failure and drug resistance to…
- Trial name
- RESPECT (NCT03120065)
- Testing
- Electronic Dose Monitoring (MEMS)
- Where
- Kenya
- Volunteers
- 499 people
- Sponsor
- Rachel Vreeman, MD, MS
Human Immunodeficiency Virus (HIV)
Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure
This project aims to assess different antiretroviral treatment strategies, optimally controlled and conventional, in relation to drug resistance and virological treatment failure.
- Trial name
- DotArv (NCT01433601)
- Testing
- Enhanced Treatment Support (ETS)
- Where
- Vietnam
- Volunteers
- 640 people
- Sponsor
- Karolinska Institutet
HIV Infections
Safety Study of Once a Day ART and Opiate Substitute.
This study looks at HIV-infected subjects who are on methadone treatment and medicines for HIV.
- Trial name
- 3OD (NCT00324688)
- Testing
- Viread
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
HIV Infection, HIV Infections
Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens
The virological efficacy will be no different in children treated with single versus double boosted PI second line ART regimens.
- Trial name
- NCT00886990
- Testing
- ritonavir-boosted PI-based second line treatments, two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
- Where
- 8 sites in Thailand
- Volunteers
- 240 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV, Depression
Progress Pediatric Study
The purpose of this study is to study the HIV disease progression in HIV-infected Thai children.
- Trial name
- NCT01328288
- Testing
- standard ART according to the Thai Ministry of Public Health national guidelines
- Where
- 5 sites in Thailand
- Volunteers
- 840 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS.
- Trial name
- NCT00102206
- Testing
- Abacavir sulfate, Emtricitabine, Lamivudine
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Safety and Efficacy of Softgel KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)
The acute pneumonia pandemic caused by a new strain of corona virus 2019 named as COVID-19 by the World Health Organization (WHO) is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- NCT05082727
- Testing
- KOVIR (TD0068) oral softgel
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Sao Thai Duong Joint Stock Company
HIV Drug Resistance
Impact of HIV Drug Resistance Testing, and Subsequent Change to an Individualized Therapy in Tanzania
The current therapy regimens in Sub-Saharan countries, consisting of standardized first and second line drug combinations, yield a high rate of treatment failure, even within the first 12 months of therapy (23).
- Trial name
- NCT03557021
- Testing
- HIV Drug resistance testing
- Where
- 3 sites in Tanzania
- Volunteers
- 1,250 people
- Sponsor
- Medical Mission Institute, Germany
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
HIV Infections
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
This 2 arm study will assess the efficacy and safety of a new regimen of Fuzeon + optimized background antiretroviral treatment, in Fuzeon-naive HIV-1 infected patients with virological failure.
- Trial name
- NCT00615134
- Testing
- enfuvirtide [Fuzeon], Optimized background ARV therapy
- Where
- 30 sites in France
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus
Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy
Background: The human immunodeficiency virus (HIV) causes acquired immune deficiency syndrome (AIDS). Combination antiretroviral therapy (ART) drugs treat HIV infection.
- Conditions
- Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, AIDS Virus, Human Immunodeficiency Virus
- Trial name
- NCT01976715
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen
The investigators hypothesize that following virological failure of a standard NNRTI+2N(T)RTI regimen second-line antiretroviral therapy consisting of ritonavir-boosted lopinavir and 2N(T)RTIs will offer comparable efficacy to…
- Trial name
- SECOND-LINE (NCT00931463)
- Testing
- raltegravir, 2N(t)RTI, Ritonavir-boosted lopinavir
- Where
- 44 sites in Argentina, Australia and 15 more
- Volunteers
- 558 people
- Sponsor
- Kirby Institute
HIV Infections
A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment
The purpose of this study is to see if adding 1 or 2 drugs to the anti-HIV therapy of patients whose HIV levels increased while taking their anti-HIV drugs can lower viral load (amount of HIV in the blood) and keep it low up to…
- Trial name
- NCT00006152
- Testing
- Ritonavir, Abacavir sulfate, Amprenavir
- Where
- 13 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hiv, Drug Resistancy
The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART
This is a prospective observational cohort study of 2820 patients on first-line ART switching to a DTG-based first-line regimen, according to the standard of care.
- Conditions
- Hiv, Drug Resistancy, Virologic Failure
- Trial name
- DTG-SWITCH (NCT04612452)
- Where
- 2 sites in Malawi, Zambia
- Volunteers
- 2,820 people
- Sponsor
- University of Bern
Acute-on-Chronic Liver Failure (ACLF), hepatitisB
The Relationship Between Novel Virological Indicators and Treatment With Different Nucleotide Analogues and the Prognosis of HBV-ACLF Patients
This is an observational study. This study mainly explores the dynamic changes of HBV RNA and HBcrAg during the treatment of HBV-ACLF, as well as the safety of entecavir (ETV), tenofovir alafenamide (TAF) and tenofovir…
- Conditions
- Acute-on-Chronic Liver Failure (ACLF), hepatitisB, Treatment
- Trial name
- NCT07815418
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Tongji Hospital
HIV
Structured Treatment Interruption for HIV Patients With Virologic Failure
The purpose of this study is to assess the virologic impact of switching treatment-experienced HIV-infected patients with virologic failure to a salvage regimen with or without a 12 week STI prior to the switch.
- Trial name
- NCT00188851
- Testing
- therapeutic management strategy
- Volunteers
- 196 people
- Sponsor
- University Health Network, Toronto
HIV, AIDS
Resistance Testing to Improve Management of Virologic Failure in Sub-Saharan Africa
The study design is an open-label, randomized controlled trial. The study will be conducted at study sites in Uganda and South Africa.
- Trial name
- REVAMP (NCT02787499)
- Testing
- HIV-1 RNA Resistance Testing
- Where
- 2 sites in South Africa, Uganda
- Volunteers
- 840 people
- Sponsor
- Massachusetts General Hospital
Virus Disease
Collection of Liver Tissue for Virologic Studies
This study will examine liver tissue to investigate the role of viral infections in fulminant hepatitis, liver failure, and profound bone marrow failure.
- Trial name
- NCT00005936
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HIV Infections
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
Group A: To compare the time to confirmed virologic failure (2 consecutive plasma HIV-RNA concentrations of 500 copies/ml or more) between the treatment arms: abacavir (ABC) or placebo in combination with zidovudine (ZDV)…
- Trial name
- NCT00000885
- Testing
- Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 440 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
Ritonavir (RTV) is a protease inhibitor (PI) commonly used to increase drug levels of other PIs in HIV drug treatment. The purpose of this study is to compare a combination of drugs which includes RTV and 2 protease inhibitors…
- Trial name
- NCT00028366
- Testing
- Fosamprenavir, Lopinavir/Ritonavir, Ritonavir
- Where
- 13 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)